XML 23 R7.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Operating activities      
Net loss $ (112,444,000) $ (106,794,000) $ (90,722,000)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 2,257,000 1,365,000 1,404,000
Write-off of assets in progress 862,000    
Loss (gain) on disposal of property and equipment 91,000 46,000 (24,000)
Accretion of discounts and amortization of premiums on marketable securities 178,000 660,000 881,000
Unoccupied facility expense     386,000
Accretion of debt discount related to debt financing   (115,000)  
Cash-settled portion of stock compensation expense 602,000 387,000 0
Stock compensation expense 14,126,000 9,316,000 6,089,000
Loss on extinguishment of debt   1,671,000  
Changes in operating assets and liabilities:      
Accounts and other receivables 52,000 (667,000) 900,000
Prepaid expenses and other current assets 560,000 1,631,000 (2,683,000)
Restricted cash and other assets (103,000) (211,000) 277,000
Accounts payable 1,181,000 1,246,000 (523,000)
Accrued liabilities and other long term liabilities (11,759,000) 9,017,000 4,810,000
Deferred revenues (2,654,000) (10,111,000) 5,467,000
Net cash used in operating activities (107,051,000) (92,559,000) (73,738,000)
Investing activities      
Purchases of marketable securities (126,754,000) (208,936,000) (44,807,000)
Proceeds from maturities of marketable securities 220,760,000 130,110,000 137,071,000
Purchases of property and equipment, net (7,757,000) (6,970,000) (1,667,000)
Net cash provided by (used in) investing activities 86,249,000 (85,796,000) 90,597,000
Financing activities      
Proceeds from issuances of common stock, net   183,897,000  
Payment of debt   (10,988,000)  
(Withholding) proceeds from exercise of stock options and restricted stock awards, net (84,000) 531,000 49,000
Proceeds from Employee Stock Purchase Plan 615,000 291,000 130,000
Proceeds from exercise of warrants   228,000 163,000
Proceeds from long-term debt, net     9,559,000
Net cash provided by financing activities 531,000 173,959,000 9,901,000
Effect of exchange rate changes on cash and cash equivalents (252,000) (303,000) (371,000)
Net (decrease) increase in cash and cash equivalents (20,523,000) (4,699,000) 26,389,000
Cash and cash equivalents at beginning of year 44,812,000 49,511,000 23,122,000
Cash and cash equivalents at end of year 24,289,000 44,812,000 49,511,000
Supplemental disclosure of cash flow information      
Cash paid during the year for interest   720,000  
Accrual for litigation settlement and insurance recovery 4,975,000    
Non-cash investing and financing activities:      
Disposal of fully depreciated property and equipment 2,354,000 1,436,000 841,000
Net change in unrealized (loss) gain on marketable securities (8,000) $ 11,000 $ 32,000
Astra Zeneca      
Supplemental disclosure of cash flow information      
Return of unused development funding to AstraZeneca AB “AstraZeneca” (Note 9) 7,200,000    
Milestone payment from AstraZeneca (Note 9) $ 7,200,000